Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-28
2008-03-18
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
07345042
ABSTRACT:
The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure:where the substituents are as defined herein.
REFERENCES:
patent: 6391865 (2002-05-01), Baroudy et al.
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (2001).
Bara Thomas A.
Clader John W.
Josien Hubert B.
Li Shengjian
McBriar Mark D.
Bernhardt Emily
Kalyanaraman Palaiyur S.
Lee William Y.
Schering Corporation
LandOfFree
MCH antagonists for the treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCH antagonists for the treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCH antagonists for the treatment of obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975993